Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders

share with twitter share with LinkedIn share with facebook
06/24/2020 | 06:31am EDT

TORONTO and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announces that the Board of Directors of the Corporation have considered current COVID-19 public health restrictions and determined it to be in the best interests of the Corporation and its shareholders to adjourn the Corporation’s annual meeting of shareholders (“AGM”) to 9:00 a.m. (Pacific Time) on July 29, 2020 and to change the location of the AGM to Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia.

Shareholders are reminded to submit their votes by proxy before the extended proxy deadline of 9:00 a.m. (Pacific Time) on Monday, July 27th, 2020. Shareholders may choose to attend the meeting by teleconference, but will not be able to vote via teleconference. All other matters of the AGM remain the same as published in the AGM proxy materials mailed to the shareholders and posted on the Corporation’s website at https://promisneurosciences.com/ and at www.sedar.com.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes on the molecular surface of proteins. Using this unique, precision approach, ProMIS is developing novel antibody therapeutics for AD, ALS and PD. In the infectious disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. These peptide antigens can also be used to create potential therapeutic antibodies to treat active infection, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn.

To learn more about the search for therapies for Alzheimer’s, Parkinson’s and other neurodegenerative diseases, listen to the podcast, Saving Minds, at iTunes or Spotify.

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about PROMIS NEUROSCIENCES, INC.
10/14PROMIS NEUROSCIENCES : Neil Cashman to Speak at Protein Misfolding Drug Discover..
AQ
10/13PROMIS NEUROSCIENCES : rsquo; Neil Cashman to Speak at Protein Misfolding Drug D..
AQ
10/13PROMIS NEUROSCIENCES : rsquo; Neil Cashman to Speak at Protein Misfolding Drug D..
AQ
10/13ProMIS Neurosciences' Neil Cashman to Speak at Protein Misfolding Drug Disco..
GL
09/23PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
AQ
09/22PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
PU
09/22PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
AQ
09/22PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
AQ
09/22ProMIS Neurosciences to develop multivalent vaccine for Alzheimer's disease
GL
09/10PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 22nd Annual Inves..
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -6,80 M -5,19 M -5,19 M
Net Debt 2020 - - -
P/E ratio 2020 -6,60x
Yield 2020 -
Capitalization 37,7 M 28,7 M 28,8 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees -
Free-Float 90,1%
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 4,16 $
Last Close Price 0,10 $
Spread / Highest target 4 101%
Spread / Average Target 4 101%
Spread / Lowest Target 4 101%
EPS Revisions
Managers
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.-20.59%29
GILEAD SCIENCES, INC.-6.82%75 938
REGENERON PHARMACEUTICALS53.57%61 364
VERTEX PHARMACEUTICALS-2.01%57 436
WUXI APPTEC CO., LTD.63.88%38 230
BEIGENE, LTD.80.92%27 326